- Tips for Spending Holiday Time With Family Members Who Live with Dementia
- Tainted Cucumbers Now Linked to 100 Salmonella Cases in 23 States
- Check Your Pantry, Lay’s Classic Potato Chips Recalled Due to Milk Allergy Risk
- Norovirus Sickens Hundreds on Three Cruise Ships: CDC
- Not Just Blabber: What Baby’s First Vocalizations and Coos Can Tell Us
- What’s the Link Between Memory Problems and Sexism?
- Supreme Court to Decide on South Carolina’s Bid to Cut Funding for Planned Parenthood
- Antibiotics Do Not Increase Risks for Cognitive Decline, Dementia in Older Adults, New Data Says
- A New Way to Treat Sjögren’s Disease? Researchers Are Hopeful
- Some Abortion Pill Users Surprised By Pain, Study Says
Texas Lawsuit Threatens Access to Abortion Pill Nationally
MONDAY, Feb. 13, 2023 (HealthDay News) – Access to medication abortion could be at risk nationwide because of a Texas lawsuit working its way through the court system.
Alliance Defending Freedom, the group involved in the case in Mississippi that led to the Supreme Court overturning the landmark Roe v. Wade ruling, also filed this lawsuit.
The case will be decided by U.S. District Judge Matthew Kacsmaryk, who was appointed by former President Donald Trump, CBS News reported.
If the judge sides with the organization filing suit, the drug mifepristone, approved by the U.S. Food and Drug Administration nearly two decades ago, could become unavailable both in states that ban abortions and those where it is legal, CBS News reported.
The judge’s decision could also remove easier access that’s been implemented more recently, including the 2021 FDA decision not requiring women to pick up the drug in person and a 2023 decision that allowed pharmacies to dispense the drug.
“It could have an immediate impact on the country,” said Mini Timmaraju, president of NARAL Pro-Choice America, told CBS News. “In some ways, this is a backdoor ban on abortion.”
The decision could come soon after a Feb. 24 filing deadline, and would likely be appealed, CBS News reported.
The group’s allegation is that the FDA should not have used an accelerated review process for this drug, CBS News reported.
“Our representatives in Congress created the FDA and gave the FDA the responsibility to make sure that drugs are safe before they’re allowed on the market … the FDA failed that responsibility,” said Julie Blake, senior counsel for the group.
The FDA has responded that it didn’t accelerate the drug’s approval, rather that it approved it four years after the manufacturer applied, CBS News reported.
It would be “extraordinary and unprecedented” to stop distribution of the drug after so long, federal attorneys said in a legal filing.
Medication abortion has become more important since the Supreme Court’s June decision overruling Roe v. Wade, Elizabeth Nash, state policy analyst for the Guttmacher Institute, told CBS News.
Even before that decision, about half of abortions in the United States were medication abortions.
In medication abortion, a mifepristone pill is taken at up to the 10th week of pregnancy. It dilates the cervix and blocks the essential pregnancy hormone progesterone.
Another drug, misoprostol, is then taken 24 to 48 hours later, causing the uterus to contract and expel pregnancy tissue. Together, they are more than 95% effective.
“The clinics that are open in the receiving states are stretched thin, they don’t have a lot of give in their capacity and being able to provide medication abortion is very, very important,” Nash said.
More information
The group KFF has more on medication abortion.
SOURCE: CBS News
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.